Menu

The Roots of Schizophrenia

Researchers link disease-associated mutations to excitatory and inhibitory signaling in the brain.

Jun 4, 2015
Jef Akst

FLICKR, ALLAN AJIFOThe genetic causes of schizophrenia, a psychiatric disorder that affects around 1 percent of the population, are complex, to say the least. But new research has begun to produce clues pointing to the disruption of the brain’s chemical balance as the root cause of the disorder. Most recently, scientists found that genetic mutations previously linked to schizophrenia play a role in neuronal excitatory and inhibitory signaling. They published their results yesterday (June 3) in Neuron.

“We’re finally starting to understand what goes wrong in schizophrenia,” lead author Andrew Pocklington from Cardiff University’s Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics said in a press release. “We now have what we hope is a pretty sizeable piece of the jigsaw puzzle that will help us develop a coherent model of the disease, while helping us to rule out some of the alternatives.”

The same team of researchers first linked schizophrenia mutations to excitatory signaling back in 2011. The new work, which compared genetic data from 11,355 schizophrenia patients and 16,416 healthy controls, confirms these previous findings and adds inhibitory signaling to the list of functions that may be disrupted by disease-associated mutations, suggesting that it is the imbalance between the two that may be at the heart of the disorder.

“This work builds on our understanding of the genetic causes of schizophrenia, unravelling how a combination of genetic faults can disrupt the chemical balance of the brain,” Hugh Perry, chair of the MRC Neuroscience and Mental Health Board, said in the press release. “In the future, this work could lead to new ways of predicting an individual’s risk of developing schizophrenia and form the basis of new targeted treatments that are based on an individual’s genetic makeup.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.